The role of plasminogen and urokinase activator of plasminogen in the treatment of endogenous uveitis in children

Abstract

AIM: To determine the content of plasminogen and urokinase activator of plasminogen in tears and blood serum and to identify correlations between the studied parameters and the clinical picture of uveitis.

MATERIAL AND METHODS: One hundred thirty-three eyes with uveitis were examined in 74 patients aged 3 to 17 yr (average 10.45±3.35 yr). The content of the urokinase activator of plasminogen (UPA) was studied in 188 tear samples and 22 blood serum samples. The dynamics of UPA in tears were studied in 28 patients (51 eyes). The plasminogen content of 86 tear samples and 34 blood serum samples was studied. The dynamics of plasminogen in tears were studied in five patients (nine eyes). The concentrations of UPA and plasminogen were measured using the ELISA method and the kits “ELISA kit for plasminogen activator, urokinase (UPA)/ELISA Kit for Plasminogen”, Cloud-Clone Corp., USA).

RESULTS: An increase in the content of UPA in the tears of children with uveitis was associated with higher inflammatory activity (p=0.04). An increase in the content of UPA in tears was associated with an increase in the degree of proliferative changes (p=0.04). An increase in the content of UPA and plasminogen in tears was found 1–2 months after surgery. There was an increase in the content of UPA (p=0.0001) and plasminogen in tears (p=0.009) and blood serum (p=0.09) with age.

CONCLUSION: The content of UPA in tears increased significantly when severe uveitis was compared with inactive uveitis. An increase in the content of UPA in tears was associated with an increase in the degree of proliferative changes, which reflects the severity of the uveitis course. The content of UPA and plasminogen in tears and blood serum increased with age. An increase in UPA and plasminogen was observed within 1–2 months after surgery, with both returning to preoperative values by the third month of the postoperative period, which reflects the normal course of the wound healing process.

Keywords

biochemical study / blood serum / children / plasminogen / tears / urokinase plasminogen activator / uveitis

References

[1] Katargina LA, Khvatova AV. Endogennye uveity u detei i podrostkov. Moscow: Meditsina; 2000.

[2] Катаргина Л.А., Хватова А.В. Эндогенные увеиты у детей и подростков. Mосква: Медицина, 2000.

[3] Zierhut M, Michels H, Stubiger N, et al. Uveitis in Children. Int Ophthalmol Clin. 2005;45(2):135–156. doi: 10.1097/01.iio.0000155903.87679.c2

[4] Zierhut M., Michels H., Stubiger N., et al. Uveitis in Children // Int Ophthalmol Clin. 2005. Vol. 45, N 2. P. 135–156. doi: 10.1097/01.iio.0000155903.87679.c2

[5] Cunningham ET, Smith JR, Tugal-Tutkun I, et al. Uveitis in Children and Adolescents. Ocul Immunol Inflamm. 2016;24(4):365–271. doi: 10.1080/09273948.2016.1204777

[6] Cunningham E.T., Smith J.R., Tugal-Tutkun I., et al. Uveitis in Children and Adolescents // Ocul Immunol Inflamm. 2016. Vol. 24, N 4. P. 365–271. doi: 10.1080/09273948.2016.1204777

[7] Wentworth BA, Freitas-Neto CA, Foster CS. Management of pediatric uveitis. F1000Prime Rep. 2014;6:41. doi: 10.12703/P6-41

[8] Wentworth B.A., Freitas-Neto C.A., Foster C.S. Management of pediatric uveitis // F1000Prime Rep. 2014. N 6. P. 41. doi: 10.12703/P6-41

[9] Katargina LA, Chesnokova NB, Denisova EV, et al. The content of matrix metalloproteinase-9 in aqueous humor of the eyes in children with endogenous uveitis. Russian Pediatric Ophthalmology. 2022;17(3):15–21. (In Russ). doi: 10.17816/rpoj109014

[10] Катаргина Л.А., Чеснокова Н.Б., Денисова Е.В., и др. Содержание матриксной металлопротеиназы-9 во влаге передней камеры у детей с эндогенным увеитом // Российская педиатрическая офтальмология. 2022. Т. 17, № 3. С. 15–20. doi: 10.17816/rpoj109014

[11] Khrabrova MA, Chesnokova NB, Denisova EV, et al. Al’fa-2-makroglobulin pri endogennom uveite u detei. In: Neroev VV, editor. XV Rossiiskii obshchenatsional’nyi oftal’mologicheskii forum: Sb. nauch. tr.: v 2 t. Moscow; 2022. N 2. P. 450–453. (In Russ).

[12] Храброва М.А., Чеснокова Н.Б., Денисова Е.В., и др. Альфа-2-макроглобулин при эндогенном увеите у детей // XV Российский общенациональный офтальмологический форум: Сб. науч. тр.: в 2 т. / под ред. В.В. Нероева. Москва, 2022. № 2. С. 450–453.

[13] Dubrovina KA, Markova EYu, Begeeva BSh. Current trends in the treatment of ocular manifestations of children`s hypoplasminogenemia. Modern technologies in ophthalmology. 2019;4:86–90. (In Russ). doi: 10.25276/2312-4911-2019-4-86-90

[14] Дубровина К.А., Маркова Е.Ю., Бегеева Б.Ш. Современные тенденции в лечении глазных проявлений гипоплазминогенемии у детей // Современные технологии в офтальмологии. 2019. № 4. С. 86–90. doi: 10.25276/2312-4911-2019-4-86-90

[15] Pavlenko TA, Chesnokova NB, Davydova NG, et al. Level of tear endothelin-1 and plasminogen in patients with glaucoma and proliferative diabetic retinopathy. Vestnik Oftalmologii. 2013;129(4):20–23. (In Russ).

[16] Павленко Т.А., Чеснокова Н.Б., Давыдова Н.Г., и др. Содержание эндотелина и плазминогена в слезной жидкости больных глаукомой и пролиферативной диабетической ретинопатией // Вестник офтальмологии. 2013. Т. 129, № 4. С. 20–23.

[17] Aisina RB, Mukhametova LI. Structure and function of plasminogen/plasmin system. Russian Journal of Bioorganic Chemistry. 2014;40(6):642–657. (In Russ). doi: 10.7868/S0132342314060025

[18] Айсина Р.Б., Мухаметова Л.И. Структура и функции системы плазминоген/плазмин // Биоорганическая химия. 2014. Т. 40, № 6. С. 642–657. doi: 10.7868/S0132342314060025

[19] Kugaevskaya EV, Gureeva TA, Timoshenko OS, Solovyeva NI. Urokinase-Type Plasminogen Activator System in Norm and in Life-Threatening Processes (Review). General Reanimatology. 2018;14(6):61–79. (In Russ). doi: 10.15360/1813-9779-2018-6-61-79

[20] Кугаевская Е.В., Гуреева Т.А., Тимошенко О.С., Соловьева Н.И. Система активатора плазминогена урокиназного типа в норме и при жизнеугрожающих процессах (обзор) // Общая реаниматология. 2018. Т. 14, № 6. С. 61–79. doi: 10.15360/1813-9779-2018-6-61-79

[21] Jaiswal RK, Varshney AK, Yadava PK. Diversity and functional evolution of the plasminogen activator system. Biomed Pharmacother. 2018;98:886–898. doi: 10.1016/j.biopha.2018.01.029

[22] Jaiswal R.K., Varshney A.K., Yadava P.K. Diversity and functional evolution of the plasminogen activator system // Biomed Pharmacother. 2018. N 98. Р. 886–898. doi: 10.1016/j.biopha.2018.01.029

[23] Mahmood N, Mihalcioiu C, Rabbani SA. Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications. Front Oncol. 2018;8:24. doi: 10.3389/fonc.2018.00024

[24] Mahmood N., Mihalcioiu C., Rabbani S.A. Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications // Front Oncol. 2018. N 8. P. 24. doi: 10.3389/fonc.2018.00024

[25] Crippa MP. Urokinase-type plasminogen activator. Int J Biochem Cell Biol. 2007;39(4):690–694. doi: 10.1016/j.biocel.2006.10.008

[26] Crippa M.P. Urokinase-type plasminogen activator // Int J Biochem Cell Biol. 2007. Vol. 39, N 4. Р. 690–694. doi: 10.1016/j.biocel.2006.10.008

[27] Csutak A, Silver DM, Tözsér J, et al. Urokinase-type plasminogen activator to prevent haze after photorefractive keratectomy, and pregnancy as a risk factor for haze in rabbits. Invest Ophthalmol Vis Sci. 2004;45(5):1329–1333. doi: 10.1167/iovs.03-0881

[28] Csutak A., Silver D.M., Tözsér J., et al. Urokinase-type plasminogen activator to prevent haze after photorefractive keratectomy, and pregnancy as a risk factor for haze in rabbits // Invest Ophthalmol Vis Sci. 2004. Vol. 45, N 5. Р. 1329–1333. doi: 10.1167/iovs.03-0881

[29] Boiko EV, Danilichev VF, Sazhin TG, Aliev ShF. The influence of «Haemaza» administration ways on the efficiency of vitreous hemorrhage treatment in diabetic retinopathy. Ophtalmology reports. 2008;1:42–47. (In Russ).

[30] Бойко Э.В., Даниличев В.Ф., Сажин Т.Г., Алиев Ш.Ф. Влияние способов введения «Гемазы» на эффективность лечения гемофтальма при диабетической ретинопатии // Офтальмологические ведомости. 2008. № 1. С. 42–47.

[31] Sosnovskii VV, Sdobnikova SV. Use of thrombolytic agents during invasive treatments for retinal vascular occlusions. Vestnik Oftalmologii. 2007;123(5):51–54. (In Russ).

[32] Сосновский В.В., Сдобникова С.В. Использование тромболитических препаратов при инвазивных методах лечения окклюзий ретинальных сосудов // Вестник офтальмологии. 2007. Т. 123, № 5. С. 51–54.

[33] Sosnovskii VV, Sdobnikova SV, Revishchin AV, et al. Surgical treatment policy using recombinant prourokinase for submacular hemorrhages. Vestnik Oftalmologii. 2009;125(4):3–8. (In Russ).

[34] Сосновский В.В., Сдобникова С.В., Ревищин А.В., и др. Тактика хирургического лечения субмакулярных кровоизлияний с использованием рекомбинантной проурокиназы // Вестник офтальмологии. 2009. Т. 125, № 4. С. 3–8.

[35] O’Rourke J, Lindsay M, Kreutzer D, et al. Evidence of impaired anterior segment fibrinolytic activity in chronic uveitis. Ophthalmic Res. 1982;14(4):256–264. doi: 10.1159/000265200

[36] O’Rourke J., Lindsay M., Kreutzer D., et al. Evidence of impaired anterior segment fibrinolytic activity in chronic uveitis // Ophthalmic Res. 1982. Vol. 14, N 4. Р. 256–264. doi: 10.1159/000265200

[37] Jabs DA, Nussenblatt RB, Rosenbaum JT, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–516. doi: 10.1016/j.ajo.2005.03.057

[38] Jabs D.A., Nussenblatt R.B., Rosenbaum J.T., et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop // Am J Ophthalmol. 2005. Vol. 140, N 3. Р. 509–516. doi: 10.1016/j.ajo.2005.03.057

[39] Petrovskaya MS, Denisova EV, Slepova OS, Katargina LA. The role of infectious factors in the development of proliferative syndrome in the children presenting with endogenous uveitis. Russian Pediatric Ophthalmology. 2012;7(2):28–31. (In Russ). doi: 10.17816/rpoj37456

[40] Петровская М.С., Денисова Е.В., Слепова О.С., Катаргина Л.А. Роль инфекционных факторов в развитии пролиферативного синдрома при эндогенных увеитах у детей // Российская педиатрическая офтальмология. 2012. Т. 7, № 2. С. 8–31. doi: 10.17816/rpoj37456

[41] Vaday GG, Lider O. Extracellular matrix moieties, cytokines, and enzymes: dynamic effects on immune cell behavior and inflammation. J Leukoc Biol. 2000;67(2):149–159. doi: 10.1002/jlb.67.2.149

[42] Vaday G.G., Lider O. Extracellular matrix moieties, cytokines, and enzymes: dynamic effects on immune cell behavior and inflammation // J Leukoc Biol. 2000. Vol. 67, N 2. Р. 149–159. doi: 10.1002/jlb.67.2.149

[43] Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays. 1993;15(2):105–111. doi: 10.1002/bies.950150206

[44] Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness // Bioessays. 1993. Vol. 15, N 2. Р. 105–111. doi: 10.1002/bies.950150206

[45] Del Rosso M, Fibbi G, Pucci M, et al. The plasminogen activation system in inflammation. Front Biosci. 2008;13:4667–4686. doi: 10.2741/3032

[46] Del Rosso M., Fibbi G., Pucci M., et al. The plasminogen activation system in inflammation // Front Biosci. 2008. N 13. Р. 4667–4686. doi: 10.2741/3032

[47] Del Rosso M, Fibbi G, Matucci Cerinic M. The urokinase-type plasminogen activator system and inflammatory joint diseases. Clin Exp Rheumatol. 1999;17(4):485–498.

[48] Del Rosso M., Fibbi G., Matucci Cerinic M. The urokinase-type plasminogen activator system and inflammatory joint diseases // Clin Exp Rheumatol. 1999. Vol. 17, N 4. Р. 485–498.

[49] Volodin NN, Roytman EV, Rumyantsev AG, Shneyder MM. Thromboses in the neonate: pathogenesis, diagnosis, treatment. Clinical Practice in Pediatrics. 2012;7(4):34–43. (In Russ).

[50] Володин Н.Н., Ройтман Е.В., Румянцев А.Г., Шнейдер М.М. Тромбозы у новорожденных: патогенез, диагностика, лечение // Вопросы практической педиатрии. 2012. Т. 7. № 4. Р. 34–43.

[51] Fallah M, Viklund E, Bäckman A, et al. Plasminogen is a master regulator and a potential drug candidate for the healing of radiation wounds. Cell Death Dis. 2020;11(3):201. doi: 10.1038/s41419-020-2397-0.

[52] Fallah M., Viklund E., Bäckman A., et al. Plasminogen is a master regulator and a potential drug candidate for the healing of radiation wounds // Cell Death Dis. 2020. Vol. 11, N 3. P. 201. doi: 10.1038/s41419-020-2397-0.

RIGHTS & PERMISSIONS

Eco-Vector